While Elizabeth Holmes and Theranos’ “fake it till you make it” approach to wooing investors has been in the headlines once again, another Silicon Valley company is at the heart of an intellectual property lawsuit currently making its way through the Texas court system that follows a similar method.

HouseCanary Inc., a San Francisco-based startup company, is in the midst of legal proceedings with a title company, Title Source. Interestingly, the Title Source v. HouseCanary case draws some concerning parallels with failed blood-testing startup Theranos and the causes of its downfall: a startup overpromising and under-delivering, deception from executives, whistleblowers whistleblowing, and investors ultimately paying the price. Title Source has been bouncing around the state’s legal system for several years and the ultimate ruling could have consequences that extend beyond the Lone Star State’s borders.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]